BAC Completes Feasibility Study in Providing Selective Ligands for Genmab’s UniBody® Platform
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
BAC BV has announced that it successfully completed a feasibility study in its collaboration with Genmab A/S (Copenhagen, Denmark), an international biotechnology company developing human antibody therapeutics for the potential treatment of cancer.
Under this collaboration, BAC developed CaptureSelect® custom affinity ligands for use in monitoring Genmab UniBody® drug candidates in preclinical studies and clinical trials and delivered positive results from the initial feasibility study.
UniBody® is Genmab’s proprietary antibody technology for creating a monovalent non-activating and stable antibody format with an anticipated longer therapeutic window than current small antibody formats. UniBody® molecules are based on human IgG4 antibodies, and consist of only one heavy and one light chain. UniBody® molecules are suitable as therapeutics when monovalent binding to the target is required and no immune effector functions are desired, for instance for the treatment of asthma, inflammation, and cardiovascular and infectious diseases.
BAC’s affinity ligands for UniBody® molecules were designed to distinguish between monovalent UniBody® molecules and native IgG4 antibodies, thereby avoiding binding to the Fab-domain of the UniBody®. Despite the high similarity between the related proteins, BAC’s UniBody®-specific affinity ligands did not show any cross-binding to other mammalian IgG4 molecules.
“We are delighted to have completed the feasibility study on the custom-made CaptureSelect® affinity ligands for Genmab,” said Dr. Laurens Sierkstra, CEO of BAC. “Besides the lack of the hinge region, some of Genmab’s monovalent UniBody® molecules differ only in a few amino acids compared to the native homodimer IgG4 molecules, and the challenge was to create affinity ligands targeting those regions. This success further confirms that our CaptureSelect platform can consistently produce highly specific affinity ligands and can discriminate between proteins differing in only a few amino acids.”
Under this collaboration, BAC developed CaptureSelect® custom affinity ligands for use in monitoring Genmab UniBody® drug candidates in preclinical studies and clinical trials and delivered positive results from the initial feasibility study.
UniBody® is Genmab’s proprietary antibody technology for creating a monovalent non-activating and stable antibody format with an anticipated longer therapeutic window than current small antibody formats. UniBody® molecules are based on human IgG4 antibodies, and consist of only one heavy and one light chain. UniBody® molecules are suitable as therapeutics when monovalent binding to the target is required and no immune effector functions are desired, for instance for the treatment of asthma, inflammation, and cardiovascular and infectious diseases.
BAC’s affinity ligands for UniBody® molecules were designed to distinguish between monovalent UniBody® molecules and native IgG4 antibodies, thereby avoiding binding to the Fab-domain of the UniBody®. Despite the high similarity between the related proteins, BAC’s UniBody®-specific affinity ligands did not show any cross-binding to other mammalian IgG4 molecules.
“We are delighted to have completed the feasibility study on the custom-made CaptureSelect® affinity ligands for Genmab,” said Dr. Laurens Sierkstra, CEO of BAC. “Besides the lack of the hinge region, some of Genmab’s monovalent UniBody® molecules differ only in a few amino acids compared to the native homodimer IgG4 molecules, and the challenge was to create affinity ligands targeting those regions. This success further confirms that our CaptureSelect platform can consistently produce highly specific affinity ligands and can discriminate between proteins differing in only a few amino acids.”
